The first half of 2025 is confirming what many corporate finance leaders anticipated: cross-border mergers and acquisitions are not merely recovering — they are structurally reshaping entire sectors. In a single week, two landmark transactions — Merck KGaA’s $11.3 billion acquisition of Bio-Techne and ON Semiconductor’s $7 billion all-stock deal for Synaptics — have crystallised the dominant logic driving boardroom decisions across life sciences, semiconductor technology, and physical AI infrastructure. For CFOs, General Counsel, and M&A Directors navigating this environment, the signals are clear and the window for strategic positioning is narrowing.

Life Sciences and AI Chips: Two Sectors, One Strategic Imperative

Merck KGaA’s move to acquire Bio-Techne represents the German pharmaceutical and technology group’s largest transaction in over a decade, and its implications extend well beyond the deal itself. Bio-Techne, a Minneapolis-based life sciences tools company, provides Merck with critical capabilities in proteomics, immunoassays, and biologics — competencies that are increasingly central to drug discovery pipelines powered by artificial intelligence. The $11.3 billion valuation reflects a premium on proprietary data assets and specialised scientific infrastructure, not merely revenue multiples.

Simultaneously, ON Semiconductor’s acquisition of Synaptics — structured as an all-stock transaction — signals a different but equally deliberate logic: consolidation in the AI-enabled device ecosystem, where edge computing and human-machine interface technologies are converging. The $7 billion deal positions ON Semi to compete more aggressively in automotive and industrial AI applications, sectors where physical AI infrastructure is becoming a decisive competitive moat.

Together, these transactions illustrate a maturing M&A thesis: acquirers are no longer buying revenue — they are buying technological optionality and data-driven differentiation at scale.

European Consolidation: Defence, Energy, and Consumer Health in Motion

Beyond the headline deals, a parallel wave of European-led consolidation is underway across adjacent sectors. Safran’s exclusive negotiations to acquire Exail Technologies at €128.5 per share reflect the accelerating roll-up of dual-use maritime and drone technology assets within the French defence industrial base — a trend directly linked to increased NATO spending commitments and the European Defence Fund’s evolving procurement priorities.

KKR’s agreement to acquire EDF Power Solutions in the United States and Canada from EDF demonstrates the continued appetite of private equity for cross-border energy asset divestitures, particularly as European utilities rationalise their international footprints under regulatory and balance sheet pressure. For corporate finance teams, this transaction is a reminder that state-adjacent assets remain highly liquid when structured correctly for institutional buyers.

In consumer health, Haleon’s bid for Thorne — a U.S. supplements firm — targets a $70 billion addressable market where brand equity, clinical substantiation, and direct-to-consumer distribution are increasingly valued by strategic acquirers. This mid-market deal reflects a broader pattern: large-cap consumer health companies are using bolt-on acquisitions to access growth segments that organic R&D cannot reach efficiently.

Due Diligence and Post-Merger Integration: Where Deals Are Won or Lost

Not all transactions this week have proceeded without friction. CoreWeave’s $9 billion offer for Core Scientific is facing significant backlash, underscoring the heightened scrutiny applied to private equity-backed infrastructure deals — particularly where AI infrastructure valuations are perceived as speculative rather than grounded in durable cash flow. This development is a timely reminder for deal teams that due diligence rigour and post-merger integration planning are non-negotiable, especially in sectors where asset valuations are driven by forward-looking AI revenue assumptions.

Key considerations for M&A Directors and General Counsel managing cross-border transactions in the current environment include:

  • Regulatory mapping: Cross-border deals involving AI, semiconductors, or defence-adjacent technologies are subject to heightened foreign direct investment (FDI) screening under frameworks including the EU’s FDI Screening Regulation and CFIUS in the United States.
  • Valuation discipline: All-stock structures, as seen in the ON Semi–Synaptics deal, require robust fairness opinion processes and independent board-level review to withstand shareholder and regulatory scrutiny.
  • Integration sequencing: In life sciences and technology acquisitions, retaining key scientific and engineering talent post-close is frequently more value-critical than financial synergy realisation in year one.

Key Takeaway for Decision-Makers

The current M&A cycle is characterised by strategic precision over volume. Acquirers with clearly defined technology theses — whether in life sciences tools, AI-enabled semiconductors, or defence technology — are executing at scale and at premium valuations. For boards and executive teams evaluating their own corporate finance strategies, the imperative is to define acquisition criteria with the same rigour applied to organic investment decisions, and to ensure that cross-border deal structures are designed from the outset to withstand both regulatory review and post-merger integration complexity. In a market moving this quickly, preparation is the only sustainable competitive advantage.